PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1475410-3	1992	L-364,718, a selective antagonist of CCK-A receptors, caused further increase in gastric HCl and plasma gastrin responses to duodenal peptone but reduced the pancreatic protein outputs in these tests by about 75%.	l-364	0-5	cholecystokinin	Canis lupus familiaris	37-40	
8769975-0	1996	Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.	l-364	39-44	cholecystokinin	Canis lupus familiaris	24-27	
8098910-4	1993	Consistent with this observation was our finding that the CCK-A receptor selective antagonist L-364,718 dose dependently (10(-11)-10(-7) M) inhibited CCK-mediated somatostatin release but at the same doses did not alter the effect of gastrin.	l-364	94-99	cholecystokinin	Canis lupus familiaris	58-61	
1636140-6	1992	On separate days, the dogs were pretreated with the specific CCK receptor antagonist L-364,718.	l-364	85-90	cholecystokinin	Canis lupus familiaris	61-64	
2210484-7	1990	Pretreatment with a highly selective CCK receptor antagonist L-364 (1 mg/kg i.v.)	l-364	61-66	cholecystokinin	Canis lupus familiaris	37-40	
1403819-6	1992	The CCK receptor antagonist L-364,718 caused a further increase in the postprandial HCl secretion from the HP and in the plasma levels of gastrin and CCK but pancreatic output of protein and plasma concentration of somatostatin were significantly reduced.	l-364	28-33	cholecystokinin	Canis lupus familiaris	4-7	
1403819-6	1992	The CCK receptor antagonist L-364,718 caused a further increase in the postprandial HCl secretion from the HP and in the plasma levels of gastrin and CCK but pancreatic output of protein and plasma concentration of somatostatin were significantly reduced.	l-364	28-33	cholecystokinin	Canis lupus familiaris	150-153	
1403819-14	1992	Administration of L-364,718 resulted in a further increase in the HCl response of HP to bombesin and in plasma levels of gastrin and CCK but caused a reduction in plasma levels of somatostatin.	l-364	18-23	cholecystokinin	Canis lupus familiaris	133-136	
2721318-3	1989	Exogenous CCK-8 infused intravenously in gradually increasing doses (12.5-400 pmol/kg/hr) caused a dose-dependent increase in plasma PP from basal 28 +/- 4 pM to 136 +/- 18 pM, and this PP increase was completely suppressed by both intravenous and intraduodenal administration of L-364,718.	l-364	280-285	cholecystokinin	Canis lupus familiaris	10-13